Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, a functionally selective muscarinic (M1) agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well-tolerated in healthy young adult males, as well as in healthy elderly males and females.

The purpose of the Phase I trial was to investigate the safety, tolerability and pharmacokinetics of multiple doses of NGX267 and to confirm data from previous studies in which NGX267 demonstrated evidence of muscarinic receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ages of 18 and 55, were enrolled in the double-blind, placebo-controlled trial conducted at one center in Belgium. In a series of sequential dosing cohorts, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once-daily for four consecutive days. NGX267 was well tolerated at doses up to and including 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances. TorreyPines plans to initiate a Phase II dose-ranging trial in CIAS during the first half of 2008.

A secondary objective was to obtain quantitative measures of salivary flow, prior to and at multiple time points post-dosing, as a peripheral biomarker for stimulation of the muscarinic receptor. In the study, increases in peak and total sal
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... and SYDNEY , May 16, 2013 /PRNewswire/ ... HIN), a leading innovator of less invasive, miniaturized circulatory support ... today announced that CEO Doug Godshall ... Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  ... Sheraton New York Hotel. A live webcast of ...
(Date:5/16/2013)... REDWOOD CITY, Calif. , May 16, 2013 ... pharmaceutical company focused on the development and commercialization of innovative ... announced that Richard King , President and ... Healthcare Conference at the Sheraton New York Hotel in ... for Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. ...
(Date:5/16/2013)... Developers of a pill bottle that wirelessly transmits data, measures ... winners in the Healthcare Innovation World Cup , the ... by HITLAB . Winning team members ... and Mike Morena of Team ... will receive $50,000 in prize money. They earned the ...
Breaking Medicine Technology:HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5
... WASHINGTON, Sept. 27, 2011 Nearly three quarters ... comprised of products imported from developed markets, but the next ... developed specifically for the unique needs of the India market, ... PRTM Management Consulting , which were presented today at AdvaMed ...
... 2011 Critical information that dietary supplement manufacturers ... Food & Drug Administration,s (FDA) good manufacturing practices ... paper available at http://www.microtestlabs.com/dietarypaper . ... A New Paradigm for Manufacturers ," provides how-to ...
Cached Medicine Technology:Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 3New White Paper for Dietary Supplement Manufacturers Provides How-to for New FDA Compliance Paradigm 2New White Paper for Dietary Supplement Manufacturers Provides How-to for New FDA Compliance Paradigm 3
(Date:5/18/2013)... News) -- Just a few extra cups of coffee ... autoimmune liver disease known as primary sclerosing cholangitis (PSC), ... Clinic in Rochester, Minn., found that drinking coffee was ... which can lead to cirrhosis of the liver, liver ... prove a cause-and-effect relationship. "While rare, PSC ...
(Date:5/18/2013)... use of a smartphone application significantly improves patients, ... presented today at Digestive Disease Week (DDW). The ... the procedure, includes dietary restrictions and requires specific ... intervals. The better the preparation, the easier it ... polyps in the colon. The study, which was ...
(Date:5/18/2013)... -- Regular consumption of coffee is associated with ... an autoimmune liver disease, Mayo Clinic research shows. ... Disease Week 2013 conference in Orlando, Fla. ... bile ducts that results in inflammation and subsequent ... liver, liver failure and biliary cancer. , "While ...
(Date:5/18/2013)... 18, 2013 Assisted living and ... to safety and comfort of their residents. Systems ... clients with an effective and cost-efficient solution – ... an integrated, turnkey communications solution that helps nurses ... residents independence and privacy. , The VisionLink ...
(Date:5/18/2013)... 2013 Today, Zane Benefits, Inc. ... role in Marketplaces . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... (HHS) recently released a much-anticipated statement and Q&A ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4
... American Speech-Language-Hearing Association (ASHA) has announced plans to award ... of the Association for her pioneering research and academic ... Chair in Communication Disorders in the School of Behavioral ... research in the Callier Center for Communication Disorders. In ...
... INDIANAPOLIS Technologies for rapid detection of bacterial ... supply. Researchers from the School of ... the Bindley Bioscience Center at Purdue University have ... classification of harmful bacteria in food. The investigators ...
... in the Oct. 15 issue of the Journal of ... a much higher prevalence and risk of restless legs syndrome ... may improve sleep and quality of life in people with ... syndrome was about 10 times higher in the fibromyalgia group ...
... precursors of all the tissues in our body, can ... cancer. Now research from Rockefeller University shows that having ... for too long, can increase the odds of developing ... death in precursor cells for blood, or hematopoietic stem ...
... known as beta blockers have been proven to increase patients, ... workload and oxygen demand on the heart. In a breakthrough ... Medicine cardiologist Jeffrey J. Goldberger found the majority of patients ... drugs, which can put their recovery from heart attacks and ...
... HealthDay Reporter , THURSDAY, Oct. 14 (HealthDay News) ... follows all the recommended colon cancer screening guidelines, a new ... for some tests, while the remaining 40 percent don,t follow ... "There,s more work to be done to understand how to ...
Cached Medicine News:Health News:Award to honor pivotal career in speech research 2Health News:Award to honor pivotal career in speech research 3Health News:Eat safer: Novel approach detects unknown food pathogens 2Health News:Study finds a high rate of restless legs syndrome in adults with fibromyalgia 2Health News:Gene identified that prevents stem cells from turning cancerous 2Health News:Gene identified that prevents stem cells from turning cancerous 3Health News:Low beta blocker dose can put patients at risk for subsequent heart attacks 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 3
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
9mm Gently Curved Jaws, WIth Lock, in Titanium....
5mm Gently Curved Wing Span, With Centering Pin, Low Profile; in stainless steel....
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
Medicine Products: